Aristotle Capital Boston LLC Has $8.42 Million Position in Avid Bioservices, Inc. (NASDAQ:CDMO)

Aristotle Capital Boston LLC decreased its holdings in shares of Avid Bioservices, Inc. (NASDAQ:CDMO) by 11.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 681,999 shares of the biopharmaceutical company’s stock after selling 84,341 shares during the period. Aristotle Capital Boston LLC owned approximately 1.07% of Avid Bioservices worth $8,423,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. AQR Arbitrage LLC acquired a new stake in shares of Avid Bioservices in the 4th quarter worth about $19,386,000. Nexpoint Asset Management L.P. bought a new stake in Avid Bioservices during the 4th quarter worth approximately $22,902,000. One68 Global Capital LLC purchased a new stake in shares of Avid Bioservices in the fourth quarter worth approximately $333,000. Schonfeld Strategic Advisors LLC lifted its holdings in shares of Avid Bioservices by 157.4% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 546,414 shares of the biopharmaceutical company’s stock valued at $6,748,000 after purchasing an additional 334,164 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in shares of Avid Bioservices by 757.3% during the fourth quarter. Tudor Investment Corp ET AL now owns 101,192 shares of the biopharmaceutical company’s stock valued at $1,250,000 after buying an additional 89,389 shares during the last quarter. 97.16% of the stock is owned by institutional investors.

Avid Bioservices Trading Up 0.1 %

Shares of Avid Bioservices stock opened at $12.50 on Friday. The company has a market capitalization of $799.18 million, a P/E ratio of -5.23 and a beta of 1.39. The stock has a fifty day simple moving average of $12.50 and a 200 day simple moving average of $12.17. Avid Bioservices, Inc. has a 12-month low of $6.53 and a 12-month high of $12.51. The company has a current ratio of 1.30, a quick ratio of 0.92 and a debt-to-equity ratio of 3.58.

About Avid Bioservices

Avid Bioservices, Inc operates as a contract development and manufacturing organization for the biotechnology and biopharmaceutical industries in the United States. It provides process development and current good manufacturing practice clinical and commercial manufacturing services of biologics, including clinical and commercial drug substance manufacturing, bulk packaging, release and stability testing, regulatory submission and support, upstream and downstream development and optimization, analytical methods development, cell line development, testing, and characterization services.